PFE

N/A

Pfizer, Inc.

Healthcare · Rank #453 · Analyzed Jul 13, 2026

$24.17

Current Price

⚠️ Unverified — fails data-quality checks

This ticker did not clear our Definition of Done, so its valuation is shown for transparency but should not be trusted:

• Insufficient data to rate
• <2 valuation methods computed

$37.83

Intrinsic Value

+56.5%

Upside/Downside

0/10

Score

2/5

Quality

Analysis Summary

Valuation Consensus1/1 methods agree

Quality Score2/5.0

Framework RatingINSUFFICIENT DATA

Price vs Intrinsic ValueUndervalued by 56.5%

Fair Value Range

Low$28.61

Base (IV)$37.83

High$49.01

Entry Points

Conservative$20.03

Moderate$28.61

Aggressive$26.48

⚠️ Warnings

Insufficient data: fewer than 2 valuation methods

Quality & Moat Breakdown

Return on Equity8.3% → 0/1.0

Debt LevelD/E 72 → 0/1.0

Revenue QualityInsufficient data +recovery → 0.5/1.0

Moat Strength3.5/5 → 0.5/1.0

Profit Margins11.8% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.